A Phase 2/3 interventional study of PRO 140 (350 mg) and PRO 140 (525 mg) in HIV, sponsored by CytoDyn, Inc.. Completed at 12 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-04.
Sponsored by CytoDyn, Inc. · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study is a Phase 2b/3, multi-center study designed to evaluate the efficacy, safety, and tolerability of the strategy of shifting clinically stable patients receiving suppressive combination antiretroviral therapy to PRO 140 monotherapy and maintaining viral suppression for 48 weeks following study entry.
Consenting patients will be shifted from combination antiretroviral regimen to weekly PRO 140 monotherapy for 48 weeks during the Treatment Phase with the one week overlap of existing retroviral regimen and PRO 140 at the beginning of the study treatment and also one week overlap at the end of the treatment in subjects who do not experience virologic failure.
The primary objective is to assess the treatment strategy of using PRO 140 SC as long-acting, single-agent maintenance therapy for the chronic suppression of CCR5-tropic HIV-1 infection. In addition, the prognostic factors of therapeutic success of PRO 140 monotherapy will be evaluated.
The secondary objective of the trial is to assess the clinical efficacy, safety and tolerability parameters following substitution of combination antiretroviral therapy with weekly PRO 140 monotherapy.
CytoDyn, Inc. is the lead sponsor of 24 studies on the registry; none are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 12 (100%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Laboratory values at Screening of:
Exclusion Criteria:
Treatment with any of the following:
Oral or parenteral within 30 days prior to the Screening Visit. Subjects on chronic steroid therapy > 5 mg/day will be excluded with the following exception:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
350 mg SC injections of PRO 140 per week, patients who had no Virologic Failure (VF)
Drug: PRO 140 (350 mg)
525 mg SC injections of PRO 140 per week, patients who had no Virologic Failure (VF)
Drug: PRO 140 (525 mg)
700 mg SC injections of PRO 140 per week
Drug: PRO 140 (700 mg)
525 mg SC injections of PRO 140 per week after experiencing virologic failure on 350 mg dose
Drug: PRO 140 (525 mg)
700 mg SC injections of PRO 140 per week after experiencing virologic failure on 525 mg dose
Drug: PRO 140 (700 mg)
700 mg SC injections of PRO 140 per week after experiencing virologic failure on 350 mg dose
Drug: PRO 140 (700 mg)
PRO 140 350 mg (175 mg/mL) SC injection per week
Also known as: Leronlimab
PRO 140 525 mg (175 mg/mL) SC injection per week
Also known as: Leronlimab
PRO 140 700 mg (175 mg/mL) SC injection per week
Also known as: Leronlimab
Proportion of Participants Who Remain on PRO 140 Monotherapy Regimen at the End of Week 48 Without Experiencing Virologic Failure
The proportion of participants experiencing virologic failure was analyzed and reported. Virological failure is defined as two consecutive plasma HIV-1 RNA levels of \>= 200 copies/mL.
Time frame: From T1 (first treatment administration) to week 48 (T48).
Proportion of Participants Experiencing Virologic Failure While on PRO 140 Monotherapy Regimen
Proportion of participants experiencing virologic failure while on PRO 140 monotherapy arm of the study.
Time frame: From T1 (first treatment administration) to week 48 (T48).
Time to Virologic Failure After Initiating PRO 140 Monotherapy
The average time to virologic failure after initiating PRO 140 monotherapy was measured in days for confirmed viral load. For the censored subjects (i.e. subjects who did not have an event) the date of event was the time of the last visit date. Virological failure is defined as two consecutive plasma HIV-1 RNA levels of \>= 200 copies/mL.
Time frame: From T1 (first treatment administration) to week 48 (T48).
Proportion of Participants Achieving Viral Suppression (HIV-1 RNA < 50 Copies/mL) After Experiencing Virologic Failure.
Virologic suppression was defined as plasma HIV-1 RNA levels \< 50 copies/mL as quantified by Human Immunodeficiency Virus 1 (HIV-1) Quantitative, RNA (Taqman® Real-Time PCR) assay.
Time frame: From T1 (first treatment administration) to subsequent visit when viral re-suppression achieved (up to 52 weeks).
Time to Achieving Viral Suppression (HIV-1 RNA < 50 Copies/mL) After Experiencing Virologic Failure
Virologic suppression was defined as plasma HIV-1 RNA levels \< 50 copies/mL as quantified by Human Immunodeficiency Virus 1 (HIV-1) Quantitative, RNA (Taqman® Real-Time PCR) assay.
Time frame: From T1 (first treatment administration) to subsequent visit when viral re-suppression achieved (up to 52 weeks).
Proportion of Participants With Viral Suppression (HIV-1 RNA < 50 Copies/mL) at Week 48 From the Start of PRO 140 Treatment Phase.
Virologic suppression was defined as plasma HIV-1 RNA levels \< 50 copies/mL as quantified by Human Immunodeficiency Virus 1 (HIV-1) Quantitative, RNA (Taqman® Real-Time PCR) assay.
Time frame: From T1 (first treatment administration) to week 48 (T48).
Measurement of Treatment Adherence to the PRO 140 Monotherapy Regimen
Treatment adherence in the Safety Population for all three treatment groups is provided. Measurement is proportion of subjects that reached treatment week 25 (T25)
Time frame: From T1 (first treatment administration) to week 25 (T25).
Total Time That Participants Remain Off Combination ART Regimen, Defined as the Time Between Start of PRO 140 Monotherapy and Restart of Combination ART Regimen
Total time that participants remain off combination ART regimen will be calculated, defined as the time between start of PRO 140 monotherapy and restart of combination ART Regimen.
Time frame: From T1 (first treatment administration) to last visit, up to 20 months.
Mean Change in CD4 Cell Count, at Each Visit Within the Treatment Phase
Mean change in CD4 cell count from baseline to final visit for each participant within the Treatment Phase was calculated and summarized. Visit 48 values were imputed using the last observation carried forward if missing.
Time frame: From T1 (first treatment administration) to week 48 (T48).
Proportion of Participants Within Each Treatment Group Experiencing Emerging Resistance
Proportion of participants experiencing emerging resistance exhibited by fold increase (\>= 3-fold increase) in maraviroc and PRO 140 FC (IC90 relative to wild-type virus) between baseline and the time of virologic failure, as a measure of post-baseline phenotypic resistance.
Time frame: From T1 (first treatment administration) to VF visit (up to 7 months).
Mean HIV-1 RNA Concentrations in CSF in Central Nervous System (CNS) Sub-study
Central Nervous System (CNS) sub-study Data: mean level of HIV-1 RNA in CSF (cerebrospinal fluid) at T1 (prior to first dose of PRO 140), T4, and VF visits for each treatment group.
Time frame: From T1 (first treatment administration), T4 (week 4), and VF visit (up to 7 months).
Mean PRO 140 Concentration in Plasma for Central Nervous System (CNS) Sub-study
PRO 140 concentrations were measured in plasma for a subset of participants at T1, T4, and VF timepoints. Participants contributed data only at timepoints where valid measurements were available. Timepoints with missing or invalid data were excluded.
Time frame: From T1 (first treatment administration), T4 (week 4), and VF visit (up to 7 months).
Mean PRO 140 Concentrations in CSF for Central Nervous System (CNS) Sub-study
PRO 140 concentrations were measured in CSF (cerebrospinal fluid) in a subset of participants at visits T1, T4, and VF.
Time frame: From T1 (first treatment administration), T4 (week 4), and VF visit (up to 7 months).
Mean HIV-1 RNA Concentrations in Genital Secretion in Genitourinary (GU) Sub-study
Level of HIV-1 RNA in genital secretion at T1 (prior to first dose of PRO 140), T4, and T16 visits.
Time frame: From T1 (first treatment administration), T4 visit (week 4), and T16 visit (up to 16 weeks).
Tolerability of Repeated Subcutaneous Administration of PRO 140
Tolerability of repeated subcutaneous administration of PRO 140 as assessed by study participants (using Visual Analogue Scale). Subjects were asked to mark the point that best represents the average pain intensity at the injection site on a horizontal line (100 mm in length) anchored by the following word descriptors at each end, "no pain" on the left side and "pain as bad as it could possibly be" on the right side of the line. The VAS score is determined by measuring in millimeters from the left-hand end of the line to the point that the patient marks. Possible scores range from 0 to 100, with higher scores indicating greater pain.
Time frame: From T1 (first treatment administration) to week 48 (T48)
Frequency of Grade 3 or 4 Adverse Events as Defined by the DAIDS Adverse Event Scale
Adverse Events (AEs) are presented based on severity, per Investigator discretion. Severity grades were based on the Division of Aids (DAIDS) grading guidelines. For safety analyses, Grade 3 and 4 AEs were summarized separately for treatment periods corresponding to Part 1 and Part 2 due to differences in dosing and treatment exposure. Participants who entered Part 2 (rescue treatment) received an increased dose of leronlimab and therefore constitute a distinct safety population. For this reason, AEs occurring during Part 2 are represented separately from Part 1, although Part 2 does not represent a separate study arm for efficacy analyses and participants remain attributed to their original Part 1 treatment arm in the overall study design.
Time frame: From T1 (first treatment administration) to week 48 (T48).
Frequency of Treatment-Emergent Serious Adverse Events
Serious adverse events (SAEs) that occurred during the study include all adverse events that occurred from when the subject signed the informed consent form. For safety analyses, SAEs were summarized separately for treatment periods corresponding to Part 1 and Part 2 due to differences in dosing and treatment exposure. Participants who entered Part 2 (rescue treatment) received an increased dose of leronlimab and therefore constitute a distinct safety population. For this reason, SAEs occurring during Part 2 are represented separately from Part 1, although Part 2 does not represent a separate study arm for efficacy analyses and participants remain attributed to their original Part 1 treatment arm in the overall study design.
Time frame: From T1 (first treatment administration) to week 48 (T48).
Study Start Date: 07 DEC 2016 (first subject enrolled)
| Milestone | Part 1 - 350 mg Weekly Injection, Group A | Part 1 - 525 mg Weekly Injection, Group B | Part 1 - 700 mg Weekly Injection, Group C |
|---|---|---|---|
| Started | 226 | 205 | 131 |
| Completed | 110 | 70 | 23 |
| Not completed | 116 | 135 | 108 |
| Milestone | Part 1 - 350 mg Weekly Injection, Group A | Part 1 - 525 mg Weekly Injection, Group B | Part 1 - 700 mg Weekly Injection, Group C |
|---|---|---|---|
| Started | 69 | 65 | 0 |
| Completed | 32 | 30 | 0 |
| Not completed | 37 | 35 | 0 |
The proportion of participants experiencing virologic failure was analyzed and reported. Virological failure is defined as two consecutive plasma HIV-1 RNA levels of \>= 200 copies/mL.
| proportion of participants | Part 1 - 350 mg Weekly Injections of PRO 140, Group A | Part 1 - 525 mg Weekly Injections of PRO 140, Group B | Part 1 - 700 mg Weekly Injections of PRO 140, Group C |
|---|---|---|---|
| Proportion of Participants Who Remain on PRO 140 Monotherapy Regimen at the End of Week 48 Without Experiencing Virologic Failure | 0.23 | 0.43 | 0.45 |
Proportion of participants experiencing virologic failure while on PRO 140 monotherapy arm of the study.
| proportion of participants | Part 1 - 350 mg Weekly Injections of PRO 140, Group A | Part 1 - 525 mg Weekly Injections of PRO 140, Group B | Part 1 - 700 mg Weekly Injections of PRO 140, Group C |
|---|---|---|---|
| Proportion of Participants Experiencing Virologic Failure While on PRO 140 Monotherapy Regimen | 0.66 | 0.42 | 0.41 |
The average time to virologic failure after initiating PRO 140 monotherapy was measured in days for confirmed viral load. For the censored subjects (i.e. subjects who did not have an event) the date of event was the time of the last visit date. Virological failure is defined as two consecutive plasma HIV-1 RNA levels of \>= 200 copies/mL.
| Days | Part 1 - 350 mg Weekly Injections of PRO 140, Group A | Part 1 - 525 mg Weekly Injections of PRO 140, Group B | Part 1 - 700 mg Weekly Injections of PRO 140, Group C |
|---|---|---|---|
| Time to Virologic Failure After Initiating PRO 140 Monotherapy | 136.9 ± 115.5 | 197.7 ± 132.4 | 200.6 ± 133.5 |
Virologic suppression was defined as plasma HIV-1 RNA levels \< 50 copies/mL as quantified by Human Immunodeficiency Virus 1 (HIV-1) Quantitative, RNA (Taqman® Real-Time PCR) assay.
| portion of participants | Part 1 - 350 mg Weekly Injections of PRO 140, Group A | Part 1 - 525 mg Weekly Injections of PRO 140, Group B | Part 1 - 700 mg Weekly Injections of PRO 140, Group C |
|---|---|---|---|
| Proportion of Participants Achieving Viral Suppression (HIV-1 RNA < 50 Copies/mL) After Experiencing Virologic Failure. | 0.92 | 0.79 | — |
Virologic suppression was defined as plasma HIV-1 RNA levels \< 50 copies/mL as quantified by Human Immunodeficiency Virus 1 (HIV-1) Quantitative, RNA (Taqman® Real-Time PCR) assay.
| Days | Part 1 - 350 mg Weekly Injections of PRO 140, Group A | Part 1 - 525 mg Weekly Injections of PRO 140, Group B | Part 1 - 700 mg Weekly Injections of PRO 140, Group C |
|---|---|---|---|
| Time to Achieving Viral Suppression (HIV-1 RNA < 50 Copies/mL) After Experiencing Virologic Failure | 78.6 ± 55.12 | 60.89 ± 60.33 | — |
Virologic suppression was defined as plasma HIV-1 RNA levels \< 50 copies/mL as quantified by Human Immunodeficiency Virus 1 (HIV-1) Quantitative, RNA (Taqman® Real-Time PCR) assay.
| portion of participants | Part 1 - 350 mg Weekly Injections of PRO 140, Group A | Part 1 - 525 mg Weekly Injections of PRO 140, Group B | Part 1 - 700 mg Weekly Injections of PRO 140, Group C |
|---|---|---|---|
| Proportion of Participants With Viral Suppression (HIV-1 RNA < 50 Copies/mL) at Week 48 From the Start of PRO 140 Treatment Phase. | 0.33 | 0.54 | 0.41 |
Treatment adherence in the Safety Population for all three treatment groups is provided. Measurement is proportion of subjects that reached treatment week 25 (T25)
| Participants | Part1 - 350 mg Weekly Injections of PRO 140, Group A | Part 1 - 525 mg Weekly Injections of PRO 140, Group B | Part 1 - 700 mg Weekly Injections of PRO 140, Group C |
|---|---|---|---|
| Measurement of Treatment Adherence to the PRO 140 Monotherapy Regimen | 111 | 116 | 54 |
Total time that participants remain off combination ART regimen will be calculated, defined as the time between start of PRO 140 monotherapy and restart of combination ART Regimen.
| days | Part 1 - 350 mg Weekly Injections of PRO 140, Group A | Part 1 - 525 mg Weekly Injections of PRO 140, Group B | Part 1 - 700 mg Weekly Injections of PRO 140, Group C |
|---|---|---|---|
| Total Time That Participants Remain Off Combination ART Regimen, Defined as the Time Between Start of PRO 140 Monotherapy and Restart of Combination ART Regimen | 201.53 ± 131.82 | 250.48 ± 164.43 | 273.25 ± 167.63 |
Mean change in CD4 cell count from baseline to final visit for each participant within the Treatment Phase was calculated and summarized. Visit 48 values were imputed using the last observation carried forward if missing.
| cells/uL | Part 1 - 350 mg Weekly Injections of PRO 140, Group A | Part 1 - 525 mg Weekly Injections of PRO 140, Group B | Part 1 - 700 mg Weekly Injections of PRO 140, Group C |
|---|---|---|---|
| Mean Change in CD4 Cell Count, at Each Visit Within the Treatment Phase | -41.1 ± 219.3 | -7.4 ± 217.3 | 7.6 ± 245.4 |
Proportion of participants experiencing emerging resistance exhibited by fold increase (\>= 3-fold increase) in maraviroc and PRO 140 FC (IC90 relative to wild-type virus) between baseline and the time of virologic failure, as a measure of post-baseline phenotypic resistance.
| proportion of participants | Part 1 - 350 mg Weekly Injections of PRO 140, Group A | Part 1 - 525 mg Weekly Injections of PRO 140, Group B | Part 1 - 700 mg Weekly Injections of PRO 140, Group C |
|---|---|---|---|
| Proportion of Participants Within Each Treatment Group Experiencing Emerging Resistance | 0.23 | 0.13 | 0.13 |
Central Nervous System (CNS) sub-study Data: mean level of HIV-1 RNA in CSF (cerebrospinal fluid) at T1 (prior to first dose of PRO 140), T4, and VF visits for each treatment group.
| c/mL | Part 1 - 350 mg Weekly Injections of PRO 140, Group A | Part 1 - 525 mg Weekly Injections of PRO 140, Group B | Part 1 - 700 mg Weekly Injections of PRO 140, Group C |
|---|---|---|---|
| T1 (prior to first dose) visit | — | 1.56 ± 5.60 | 1.51 ± 4.23 |
| T4 visit | — | 1.90 ± 11.93 | 1.60 ± 3.57 |
| VF visit | — | 1 ± 0 | 20.1 ± 17.6 |
PRO 140 concentrations were measured in plasma for a subset of participants at T1, T4, and VF timepoints. Participants contributed data only at timepoints where valid measurements were available. Timepoints with missing or invalid data were excluded.
| ng/mL | Part 1 - 350 mg Weekly Injections of PRO 140, Group A | Part 1 - 525 mg Weekly Injections of PRO 140, Group B | Part1 - 700 mg Weekly Injections of PRO 140, Group C |
|---|---|---|---|
| Visit T1 | 80 ± 0 | 80 ± 0 | 80 ± 0 |
| Visit T4 | 15861.03 ± 9605.10 | 21126.59 ± 8953.93 | 30672.09 ± 19165.06 |
| Visit VF | 1536.50 ± 3501.59 | 31713.25 ± 16122.03 | 16278.38 ± 24824.48 |
PRO 140 concentrations were measured in CSF (cerebrospinal fluid) in a subset of participants at visits T1, T4, and VF.
| ng/mL | Part 1 - 350 mg Weekly Injections of PRO 140, Group A | Part 1 - 525 mg Weekly Injections of PRO 140, Group B | Part 1 - 700 mg Weekly Injections of PRO 140, Group C |
|---|---|---|---|
| T1 visit | 25 ± 0 | 25 ± 0 | 25 ± 0 |
| T4 visit | 30.87 ± 16.44 | 40.84 ± 677.89 | 63.78 ± 78.47 |
| VF visit | — | 47.91 ± 47.23 | 94.27 ± 269.45 |
Level of HIV-1 RNA in genital secretion at T1 (prior to first dose of PRO 140), T4, and T16 visits.
| c/mL | Part 1 - 350 mg Weekly Injections of PRO 140, Group A | Part 1 - 525 mg Weekly Injections of PRO 140, Group B | Part 1 - 700 mg Weekly Injections for PRO 140, Group C |
|---|---|---|---|
| T1 visit | — | 1 ± 0 | 1 ± 0 |
| T4 visit | — | 1 ± 0 | 1 ± 0 |
| T16 visit | 258 ± 0 | 38.83 ± 1065.61 | — |
Tolerability of repeated subcutaneous administration of PRO 140 as assessed by study participants (using Visual Analogue Scale). Subjects were asked to mark the point that best represents the average pain intensity at the injection site on a horizontal line (100 mm in length) anchored by the following word descriptors at each end, "no pain" on the left side and "pain as bad as it could possibly be" on the right side of the line. The VAS score is determined by measuring in millimeters from the left-hand end of the line to the point that the patient marks. Possible scores range from 0 to 100, with higher scores indicating greater pain.
| score on a scale | Part 1 - 350 mg Weekly Injections of PRO 140, Group A | Part 1 - 525 mg Weekly Injections of PRO 140, Group B | Part 1 - 700 mg Weekly Injections for PRO 140, Group C |
|---|---|---|---|
| Left Side | 0.84 ± 1.30 | 0.91 ± 2.82 | 1.08 ± 1.70 |
| Right Side | 0.87 ± 1.33 | 0.90 ± 1.41 | 0.98 ± 1.94 |
Adverse Events (AEs) are presented based on severity, per Investigator discretion. Severity grades were based on the Division of Aids (DAIDS) grading guidelines. For safety analyses, Grade 3 and 4 AEs were summarized separately for treatment periods corresponding to Part 1 and Part 2 due to differences in dosing and treatment exposure. Participants who entered Part 2 (rescue treatment) received an increased dose of leronlimab and therefore constitute a distinct safety population. For this reason, AEs occurring during Part 2 are represented separately from Part 1, although Part 2 does not represent a separate study arm for efficacy analyses and participants remain attributed to their original Part 1 treatment arm in the overall study design.
| Participants | Part 1 - 350 mg Weekly Injections of PRO 140, Group A | Part 1 - 525 mg Weekly Injections of PRO 140, Group B | Part 1 - 700 mg Weekly Injections of PRO 140, Group C | Part 2 - Group A | Part 2 - Group B |
|---|---|---|---|---|---|
| Frequency of Grade 3 or 4 Adverse Events as Defined by the DAIDS Adverse Event Scale | 18 | 8 | 8 | 4 | 3 |
Serious adverse events (SAEs) that occurred during the study include all adverse events that occurred from when the subject signed the informed consent form. For safety analyses, SAEs were summarized separately for treatment periods corresponding to Part 1 and Part 2 due to differences in dosing and treatment exposure. Participants who entered Part 2 (rescue treatment) received an increased dose of leronlimab and therefore constitute a distinct safety population. For this reason, SAEs occurring during Part 2 are represented separately from Part 1, although Part 2 does not represent a separate study arm for efficacy analyses and participants remain attributed to their original Part 1 treatment arm in the overall study design.
| Participants | Part 1 - 350 mg Weekly Injections of PRO 140, Group A | Part 1 - 525 mg Weekly Injections of PRO 140, Group B | Part 1 - 700 mg Weekly Injections of PRO 140, Group C | Part 2 - Group A | Part 2 - Group B |
|---|---|---|---|---|---|
| Frequency of Treatment-Emergent Serious Adverse Events | 16 | 12 | 7 | 4 | 3 |
Collected over Adverse events were reported from the time of the first treatment visit and continued up until the final study visit, up to 22 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1 - 350 mg Weekly Injections of PRO 140, Group A | 1/226 (0.4%) | 16/226 (7.1%) | 119/226 (52.7%) |
| Part 1 - 525 mg Weekly Injections of PRO 140, Group B | 1/205 (0.5%) | 12/205 (5.9%) | 41/205 (20%) |
| Part 1 - 700 mg Weekly Injections of PRO 140, Group C | 1/131 (0.8%) | 7/131 (5.3%) | 28/131 (21.4%) |
| Part 2 - Group A | 0/69 (0%) | 4/69 (5.8%) | 30/69 (43.5%) |
| Part 2 - Group B | 0/65 (0%) | 3/65 (4.6%) | 22/65 (33.8%) |
| Event | Part 1 - 350 mg Weekly Injections of PRO 140, Group A | Part 1 - 525 mg Weekly Injections of PRO 140, Group B | Part 1 - 700 mg Weekly Injections of PRO 140, Group C | Part 2 - Group A | Part 2 - Group B |
|---|---|---|---|---|---|
| DehydrationMetabolism and nutrition disorders | 1/226 | 0/205 | 0/131 | 0/69 | 1/65 |
| SeizuresNervous system disorders | 0/226 | 0/205 | 0/131 | 0/69 | 1/65 |
| BacteremiaInfections and infestations | 0/226 | 0/205 | 0/131 | 0/69 | 1/65 |
| PneumoniaInfections and infestations | 1/226 | 1/205 | 0/131 | 1/69 | 1/65 |
| Cerebrovascular accidentNervous system disorders | 0/226 | 0/205 | 2/131 | 0/69 | 0/65 |
| Coronary Artery DiseaseCardiac disorders | 0/226 | 0/205 | 1/131 | 1/69 | 0/65 |
| Localised infectionInfections and infestations | 0/226 | 0/205 | 0/131 | 1/69 | 0/65 |
| Meningitis asepticInfections and infestations | 0/226 | 0/205 | 0/131 | 1/69 | 0/65 |
| CellulitisInfections and infestations | 0/226 | 1/205 | 0/131 | 1/69 | 0/65 |
| GastroenteritisGastrointestinal disorders | 0/226 | 2/205 | 0/131 | 0/69 | 0/65 |
| Event | Part 1 - 350 mg Weekly Injections of PRO 140, Group A | Part 1 - 525 mg Weekly Injections of PRO 140, Group B | Part 1 - 700 mg Weekly Injections of PRO 140, Group C | Part 2 - Group A | Part 2 - Group B |
|---|---|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 20/226 | 14/205 | 9/131 | 12/69 | 12/65 |
| Viral upper respiratory tract infectionInfections and infestations | 6/226 | 8/205 | 4/131 | 10/69 | 4/65 |
| DiarrhoeaGastrointestinal disorders | 20/226 | 9/205 | 5/131 | 6/69 | 6/65 |
| FatigueGeneral disorders | 19/226 | 6/205 | 5/131 | 3/69 | 3/65 |
| Injection site haemorrhageGeneral disorders | 18/226 | 6/205 | 1/131 | 5/69 | 1/65 |
| HeadacheNervous system disorders | 18/226 | 9/205 | 6/131 | 5/69 | 5/65 |
| NauseaGastrointestinal disorders | 16/226 | 7/205 | 2/131 | 4/69 | 5/65 |
| Back painMusculoskeletal and connective tissue disorders | 13/226 | 2/205 | 3/131 | 5/69 | 2/65 |
| NasopharyngitisInfections and infestations | 9/226 | 6/205 | 1/131 | 5/69 | 1/65 |
| Injection site painGeneral disorders | 14/226 | 6/205 | 1/131 | 2/69 | 0/65 |
69 participants enrolled from Part1 - Group A into Part 2 - Group A; 65 participants enrolled from Part 1 - Group B into Part 2 - Group B.
| Age, Continuous(years) | Part 1 - 350 mg Weekly Injections of PRO 140, Group A | Part 1 - 525 mg Weekly Injections of PRO 140, Group B | Part 1 - 700 mg Weekly Injections of PRO 140 Group C | Total |
|---|---|---|---|---|
| Mean | 49.9 ± 12.4 | 48.6 ± 12.9 | 49.8 ± 11.6 | 49.4 ± 12.4 |
| Sex: Female, Male(Participants) | Part 1 - 350 mg Weekly Injections of PRO 140, Group A | Part 1 - 525 mg Weekly Injections of PRO 140, Group B | Part 1 - 700 mg Weekly Injections of PRO 140 Group C | Total |
|---|---|---|---|---|
| Female | 42 | 44 | 38 | 124 |
| Male | 184 | 161 | 93 | 438 |
| Race (NIH/OMB)(Participants) | Part 1 - 350 mg Weekly Injections of PRO 140, Group A | Part 1 - 525 mg Weekly Injections of PRO 140, Group B | Part 1 - 700 mg Weekly Injections of PRO 140 Group C | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 4 | 2 | 0 | 6 |
| Asian | 4 | 3 | 0 | 7 |
| Native Hawaiian or Other Pacific Islander | 3 | 1 | 0 | 4 |
| Black or African American | 62 | 75 | 53 | 190 |
| White | 149 | 118 | 77 | 344 |
| More than one race | 2 | 2 | 0 | 4 |
| Unknown or Not Reported | 2 | 4 | 1 | 7 |
| Region of Enrollment(participants) | Part 1 - 350 mg Weekly Injections of PRO 140, Group A | Part 1 - 525 mg Weekly Injections of PRO 140, Group B | Part 1 - 700 mg Weekly Injections of PRO 140 Group C | Total |
|---|---|---|---|---|
| United States | 226 | 205 | 131 | 562 |
| Years of HIV Diagnosis(years) | Part 1 - 350 mg Weekly Injections of PRO 140, Group A | Part 1 - 525 mg Weekly Injections of PRO 140, Group B | Part 1 - 700 mg Weekly Injections of PRO 140 Group C | Total |
|---|---|---|---|---|
| Mean | 17.8 ± 9.44 | 16.6 ± 10.3 | 16.1 ± 9.16 | 17.1 ± 9.69 |
| Mean Treatment Duration(days) | Part 1 - 350 mg Weekly Injections of PRO 140, Group A | Part 1 - 525 mg Weekly Injections of PRO 140, Group B | Part 1 - 700 mg Weekly Injections of PRO 140 Group C | Total |
|---|---|---|---|---|
| Mean | 185.5 ± 125.8 | 197.4 ± 111.4 | 159.9 ± 101.36 | 189.9 ± 116 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2016 to primary completion in Sep 2020, 45 months.
Results were first posted in Mar 2026, 5 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Leronlimab